Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,489 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00574275 | Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer(VANILLA) | terminated | Phase 3 | 546 | SanofiINDUSTRY | 24 | Jun 7, 2016 | clinicaltrials |
| NCT00417209 | Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen(PAPRIKA) | completed | Phase 3 | 408 | SanofiINDUSTRY | 21 |
| Jun 3, 2016 |
| clinicaltrials |
| NCT01440088 | A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma | completed | Phase 3 | 640 | Threshold PharmaceuticalsINDUSTRY | 13 | Jun 2, 2016 | clinicaltrials |
| NCT00174837 | TRACE: Tirapazamine-Radiation And Cisplatin Evaluation(TRACE) | completed | Phase 3 | 317 | SanofiINDUSTRY | 17 | May 26, 2016 | clinicaltrials |
| NCT00602745 | S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen(S-1 Pancreas) | terminated | Phase 3 | 61 | SanofiINDUSTRY | 17 | May 26, 2016 | clinicaltrials |
| NCT00451906 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. | completed | Phase 4 | 2,252 | Hoffmann-La RocheINDUSTRY | 40 | May 24, 2016 | clinicaltrials |
| NCT01350804 | Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)(NURTURE 1) | completed | Phase 3 | 551 | Novartis PharmaceuticalsINDUSTRY | 15 | May 23, 2016 | clinicaltrials |
| NCT01585649 | PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma | completed | Phase 1 | 21 | Merckle GmbHINDUSTRY | 6 | May 18, 2016 | clinicaltrials |
| NCT00402519 | APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer | unknown | Phase 3 | 1,300 | University of Erlangen-Nürnberg Medical SchoolOTHER | 5 | May 13, 2016 | clinicaltrials |
| NCT00305188 | Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. | completed | Phase 3 | 879 | SanofiINDUSTRY | 13 | May 4, 2016 | clinicaltrials |
| NCT00631371 | Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects(INTORACT) | completed | Phase 3 | 791 | PfizerINDUSTRY | 30 | Apr 27, 2016 | clinicaltrials |
| NCT01147809 | Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag | completed | Phase 2 | 130 | GlaxoSmithKlineINDUSTRY | 13 | Apr 18, 2016 | clinicaltrials |
| NCT01390545 | VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis(VELVET) | terminated | Phase 2 | 300 | TakedaINDUSTRY | 11 | Apr 13, 2016 | clinicaltrials |
| NCT01395017 | Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer(LAPC) | completed | Phase 2 | 202 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 15 | Apr 8, 2016 | clinicaltrials |
| NCT01008475 | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer(POSEIDON) | completed | Phase 1 / Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 12 | Mar 30, 2016 | clinicaltrials |
| NCT01082549 | Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)(ECLIPSE) | completed | Phase 3 | 780 | SanofiINDUSTRY | 14 | Mar 17, 2016 | clinicaltrials |
| NCT00936221 | Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | completed | Phase 2 | 385 | AstraZenecaINDUSTRY | 12 | Mar 14, 2016 | clinicaltrials |
| NCT01297491 | Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer(BASALT-1) | completed | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 11, 2016 | clinicaltrials |
| NCT01151410 | An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age | completed | Phase 3 | 208 | Novartis PharmaceuticalsINDUSTRY | 7 | Mar 7, 2016 | clinicaltrials |
| NCT00347919 | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer | completed | Phase 2 | 189 | GlaxoSmithKlineINDUSTRY | 16 | Feb 25, 2016 | clinicaltrials |
| NCT00479752 | Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer(CORE 2) | completed | Phase 2 | 151 | Central European Cooperative Oncology GroupOTHER | 13 | Feb 18, 2016 | clinicaltrials |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | withdrawn | Phase 2 / Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 17, 2016 | clinicaltrials |
| NCT02523638 | Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients(PEN-PV) | completed | Phase 3 | 30 | AOP Orphan Pharmaceuticals AGINDUSTRY | 8 | Feb 17, 2016 | clinicaltrials |
| NCT01202591 | Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients(GLOW) | completed | Phase 1 / Phase 2 | 127 | AstraZenecaINDUSTRY | 8 | Feb 11, 2016 | clinicaltrials |
| NCT01250379 | A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA) | completed | Phase 3 | 494 | Hoffmann-La RocheINDUSTRY | 13 | Feb 11, 2016 | clinicaltrials |
| NCT01697072 | First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma(RILOMET-1) | terminated | Phase 3 | 609 | AmgenINDUSTRY | 27 | Feb 9, 2016 | clinicaltrials |
| NCT00554229 | A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases(ENTHUSE M1) | completed | Phase 3 | 896 | AstraZenecaINDUSTRY | 31 | Feb 8, 2016 | clinicaltrials |
| NCT01777932 | AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer | completed | — | 220 | Hoffmann-La RocheINDUSTRY | 1 | Feb 5, 2016 | clinicaltrials |
| NCT00297258 | Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma | completed | Phase 2 | 148 | GlaxoSmithKlineINDUSTRY | 5 | Feb 3, 2016 | clinicaltrials |
| NCT01609543 | A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations | completed | Phase 4 | 62 | Hoffmann-La RocheINDUSTRY | 3 | Feb 1, 2016 | clinicaltrials |
| NCT00982488 | Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(START rollover) | completed | Phase 2 | 238 | Bristol-Myers SquibbINDUSTRY | 24 | Jan 22, 2016 | clinicaltrials |
| NCT00900627 | Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)(THYME) | completed | Phase 1 / Phase 2 | 330 | AstraZenecaINDUSTRY | 14 | Jan 20, 2016 | clinicaltrials |
| NCT01459653 | Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor(Monitor-GCSF) | completed | — | 1,496 | SandozINDUSTRY | 12 | Jan 11, 2016 | clinicaltrials |
| NCT01140347 | A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib(REACH) | completed | Phase 3 | 565 | Eli Lilly and CompanyINDUSTRY | 27 | Dec 28, 2015 | clinicaltrials |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 165 | Sesen Bio, Inc.INDUSTRY | 18 | Dec 23, 2015 | clinicaltrials |
| NCT00699517 | A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies | completed | Phase 3 | 355 | SanofiINDUSTRY | 10 | Dec 21, 2015 | clinicaltrials |
| NCT01056341 | Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy | completed | Phase 2 / Phase 3 | 512 | Pierre Fabre DermatologyINDUSTRY | 16 | Dec 10, 2015 | clinicaltrials |
| NCT02569996 | A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma | completed | Phase 3 | 124 | Hoffmann-La RocheINDUSTRY | 1 | Dec 10, 2015 | clinicaltrials |
| NCT01223027 | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 3 | 564 | Novartis PharmaceuticalsINDUSTRY | 27 | Dec 7, 2015 | clinicaltrials |
| NCT00409188 | Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)(START) | completed | Phase 3 | 1,513 | EMD SeronoINDUSTRY | 33 | Nov 20, 2015 | clinicaltrials |
| NCT00511459 | Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients | completed | Phase 2 | 228 | AmgenINDUSTRY | 13 | Oct 29, 2015 | clinicaltrials |
| NCT01496001 | Cosmetic and Functional Outcomes After Breast Conserving Surgery | completed | N/A | 300 | National Institute of Oncology, HungaryOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01509781 | Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study | unknown | Phase 3 | 400 | National Institute of Oncology, HungaryOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01804309 | Functional Anatomical Examination of Axillary Sentinel Lymph Node Drainage in the Axillary Subregions in Early Breast Cancer | completed | — | 350 | National Institute of Oncology, HungaryOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT00373425 | A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors(RADIANT) | completed | Phase 3 | 1,252 | OSI PharmaceuticalsINDUSTRY | 19 | Sep 17, 2015 | clinicaltrials |
| NCT02553707 | A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer | completed | Phase 4 | 182 | Hoffmann-La RocheINDUSTRY | 1 | Sep 17, 2015 | clinicaltrials |
| NCT00057564 | A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma | completed | Phase 3 | 470 | Celgene CorporationINDUSTRY | 16 | Sep 11, 2015 | clinicaltrials |
| NCT00259922 | Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | completed | Phase 3 | 485 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 12 | Sep 2, 2015 | clinicaltrials |
| NCT02528747 | A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate | completed | — | 582 | Hoffmann-La RocheINDUSTRY | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01161368 | A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients | terminated | Phase 2 | 9 | Central European Cooperative Oncology GroupOTHER | 2 | Aug 13, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials